Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management
I'm PortAI, I can summarize articles.
Vivani Medical Inc. has unveiled a presentation on its subdermal semaglutide implant, NPM-139, for chronic weight management. The implant offers dosing every 6 to 12 months, unlike current GLP-1 therapies. The LIBERATE-1 study showed positive results in safety and performance. Vivani plans to start clinical trials in 2026 and expects its cash runway to last until 2027. The GLP-1 market is projected to reach $139 billion by 2030.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments